Edition:
United States

CytoDyn Inc (CYDY.PK)

CYDY.PK on OTC Markets Group

0.71USD
30 Sep 2016
Change (% chg)

$-0.01 (-1.34%)
Prev Close
$0.72
Open
$0.72
Day's High
$0.72
Day's Low
$0.69
Volume
161,490
Avg. Vol
245,293
52-wk High
$1.57
52-wk Low
$0.63

CYDY.PK

Chart for CYDY.PK

About

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors... (more)
No analyst recommendations are available for CYDY.PK.

Overall

Beta: 0.86
Market Cap(Mil.): $98.09
Shares Outstanding(Mil.): 138.22
Dividend: --
Yield (%): --

Financials

  CYDY.PK Industry Sector
P/E (TTM): -- 43.83 36.83
EPS (TTM): -0.29 -- --
ROI: -1,235.91 -0.29 13.93
ROE: -- -2.99 14.84

BRIEF-CytoDyn files for mixed shelf of up to $100 million

* Files for mixed shelf of up to $100 million - SEC filing Source text (http://bit.ly/2bmvyKu) Further company coverage:

Aug 26 2016

BRIEF-CytoDyn first patient enrolled in late-stage HIV study

* First patient enrolled under newly modified protocol in cytodyn's phase 3 pro 140 combination study in HIV Source text for Eikon: Further company coverage: (Bengaluru Newsroom +1-646-223-8780)

Jul 26 2016

Earnings vs. Estimates